Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates
- S. Capilla,
- ,
- P. Goñi,
- M. C. Rubio,
- M. T. Jiménez de Anta,
- R. Gómez-Lus
- University of Zaragoza,
- ,
- U.A.S.P.,
- Hospital Clínic – Universitat de Barcelona
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 1068-1071 (4 pages)Journal (Volume, Issue Number)
Journal of Antimicrobial Chemotherapy (Volume 53, Issue 6)Publication milestones
- Published - 06/2004
Publication status
ISSN
0305-7453Publication IDs
- Scopus: 3042685848
- PubMed: 15117921
Abstract
Objectives: The aim of this study was to determine the roles of mutations in the gyrA and parC genes and the overexpression of efflux pump(s) as mechanisms of resistance to quinolones. Forty-five Yersinia enterocolitica O:3 clinical isolates (41 nalidixic acid-resistant, three nalidixic acid-susceptible and one nalidixic acid-resistant strain obtained in vitro) were analysed. Results: All the nalidixic acid-resistant strains showed mutations in the gyrA gene and none in the parC gene. The presence of the inhibitor produced decreases in the MIC values of nalidixic acid by two to six serial dilution steps in 37 of the 41 nalidixic acid-resistant strains. Meanwhile, the MIC value of ciprofloxacin was affected in two strains whose values diminished three serial dilution steps. The nalidixic acid-resistant mutant obtained in vitro was also affected by the inhibitor decreasing the MIC value of nalidixic acid three serial dilutions steps whereas the MICs for the nalidixic acid-susceptible strains were not affected. Conclusions: Our results show that the high level of resistance to nalidixic acid is likely due to an overexpression of an efflux pump plus a mutation in the gyrA gene, whereas decreased susceptibility to ciprofloxacin is only associated with the presence of a mutation in the gyrA gene.
Funding Details
Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Sustainable Development Goals
- SDG 3 Good Health and Well
